AI is helping researchers design and screen candidates, and several drug programs have human data. PP405, peptides and follicle engineering are at different stages. Early findings are promising, but they do not establish a permanent cure or reliable restoration of every receded hairline. Compare the type of study, follow-up and regulatory status before making plans.
Compare the evidence before the headlines
Human treatment studies, isolated human follicles and mouse skin experiments answer different questions. This is an evidence map of selected developments, not a ranking of which product will work best or a complete treatment list. Study size, controls, treated area and follow-up matter more than a dramatic percentage.
| Candidate | Evidence available | What remains unproven |
|---|---|---|
| PP405 · small molecule | 78-person Phase 2a; larger Phase 2/3 recruiting | Reliable hairline restoration, durability and comparative benefit |
| GHK-Cu · copper peptide | Small human eyebrow study | Reversal of male-pattern scalp hair loss by GHK-Cu alone |
| TELODIN · peptide | Mouse experiments | Safety and effectiveness in people |
| MLPH · peptide | Isolated human follicles and mice | Results from treatment of a living human scalp |
| DualPep-ALO · peptide | Cells and isolated human scalp tissue | Patient benefit, dosing and long-term safety |
PP405: promising human data, with limits
Pelage's randomized Phase 2a enrolled 78 men and women. In the company's exploratory analysis, 31% of treated men with more advanced hair loss had a greater than 20% hair-density increase at week eight, versus 0% in the corresponding placebo subgroup, after four weeks of treatment. This is a subgroup claim, not the success rate for everyone enrolled or proof of rebuilding the temples.
The completed trial's registry has posted safety, tolerability and pharmacokinetic results. Those results should be read separately from the manufacturer's exploratory regrowth announcement; they do not turn that percentage into an independently confirmed primary efficacy result.
As checked November 2, the AWAKEN Phase 2/3 record lists recruiting status and an estimated 600 men. Its actual start is September 21, 2026; Pelage announced first-patient dosing on October 14. A larger trial is a development milestone, not approval or a release date. PP405 remains investigational, and long-term regrowth and comparative effectiveness remain open questions.
Read the source: Pelage: PP405 Phase 2a results announcement · ClinicalTrials.gov: PP405 Phase 2a, NCT06393452 · ClinicalTrials.gov: PP405 AWAKEN, NCT07819435 · Pelage: AWAKEN first-patient dosing announcement
TELODIN, MLPH and DualPep-ALO: earlier-stage research
TELODIN is a synthetic eight-amino-acid peptide studied through the telomere-protecting protein TPP1 and hair follicle stem-cell activation. The August 28 Aging Cell paper reports mouse experiments. Hair growth in this model does not establish that a peptide can restore a long-receded human hairline.
MLPH research, published online February 12 in the March 2026 journal issue, links dermal papilla IGF-1 signaling with hair shaft elongation in isolated human follicles and growth-phase effects in mice. A human follicle in a laboratory is not a clinical trial in a person.
The April 13 DualPep-ALO paper describes screening more than 200 peptides and testing growth-related effects in cells and human scalp tissue. Some laboratory measurements were comparable to minoxidil under the tested conditions. That is not evidence of equal results or safety when used on a patient's scalp.
Read the source: Aging Cell: TPP1 and hair follicle stem cells · MLPH: IGF-1 signaling and human hair shaft elongation · BMC Biotechnology: DualPep-ALO preclinical study
GHK-Cu: eyebrow findings are not scalp proof
A May 2026 proceedings report studied 18 adults using a split-eyebrow, vehicle-controlled design over 12 weeks and reported improved eyebrow hair count and thickness with a GHK-Cu serum. It is a small, short study of a different body area, not convincing evidence that GHK-Cu alone restores male-pattern scalp recession.
Cosmetic availability does not establish approval as a hair-loss drug. Injectable GHK-Cu is a separate safety question: the FDA identifies potential immune reactions from aggregation or peptide impurities and limited human safety data. Neither a cosmetic serum nor a research-paper ingredient justifies self-injection or buying an unapproved research treatment for personal use.
Read the source: GHK-Cu: small randomized split-eyebrow study · FDA: Compounding substances with potential safety risks
What the October 30 peptide review adds
The Journal of Drugs in Dermatology review identified 981 records and included 14 human studies. Its literature search was November 3, 2025, so its October 30, 2026 publication does not mean it evaluated all of this year's new findings.
The authors gave Grade B recommendations to several peptide-containing formulations, including acetyl tetrapeptide-3, biotinoyl tripeptide-1 and GHK, and Grade C to QR678 formulations. These are the review's evidence recommendations, not FDA approvals or proof of a cure. Combination products also make it difficult to isolate the contribution of one peptide; findings across hair-loss conditions cannot automatically be applied to receding male temples.
Read the source: JDD: Peptides for Hair Growth and Treatment of Hair Loss and Alopecia
How this compares with established options
The starting point is a diagnosis. A dermatologist can assess the pattern, progression and potentially recoverable hair; a transplant surgeon can assess donor supply and surgical options. There is no universal wait period or treatment sequence that fits everyone.
Discuss adverse effects before any medicine. Finasteride's label includes sexual adverse effects and postmarketing reports of persistent sexual symptoms and mood-related events. Postmarketing reports alone cannot establish frequency or causation. Your prescriber should review your history and the current label with you.
| Option | Role to discuss | Important limitation |
|---|---|---|
| Finasteride | Established prescription option for male-pattern hair loss; can slow loss and support regrowth | The Propecia label does not establish effectiveness for bitemporal recession. Benefits, contraindications and adverse effects need individual review. |
| Topical minoxidil | Established option that can support growth in responsive hair | Results vary, take time and generally require continued use; it does not guarantee a reconstructed hairline. |
| Hair transplant | Relocates available donor follicles to selected areas | Limited donor supply, surgical risks and continued loss of other hair remain relevant. Suitability and design require clinical assessment. |
Read the source: AAD: Hair loss diagnosis and treatment · DailyMed: Propecia prescribing information · AAD: Hair transplantation and continued hair loss
AI drug discovery: real programs, early evidence
AI is already being used to prioritize molecules, design candidates and guide laboratory testing for hair-loss research. These examples show active discovery programs; they do not establish how much faster the field will deliver safe, effective treatments.
A bioRxiv preprint posted June 12, 2026 describes graph neural networks and molecular screening used to identify four compounds targeting complementary follicle-related pathways. Experiments used cells and 3D follicle organoid models. The report is not peer reviewed, has disclosed commercial interests and does not demonstrate regrowth in treated patients.
XtalPi's October 2 announcement describes AI-guided design, physics-based calculations and robotic testing for a hair-loss drug program entering IND-enabling studies. This means preclinical safety, pharmacology and manufacturing work intended to support a future human-trial application. It is not permission to market a drug or evidence that it outperforms minoxidil in people.
AnHorn reported completion of a U.S. Phase 1 study of AH-001 on October 30, 2025. The company describes an AI-designed topical small molecule intended to degrade the androgen receptor and reports encouraging safety and tolerability. That sponsor announcement does not establish durable regrowth or the absence of uncommon or longer-term adverse effects.
Read the source: bioRxiv: AI-enabled discovery for hair follicle rejuvenation · XtalPi: Hair-loss program enters IND-enabling studies · AnHorn: AH-001 Phase 1 completion announcement
Reactivating a follicle is different from making a new one
The February 2026 RIKEN/OrganTech-associated study combined epithelial stem cells, dermal papilla cells and an additional mesenchymal cell population to reconstruct functioning follicle structures and cycling in experimental systems. The study involved cultured cells, engineered skin and mice, not a proven hair-cloning treatment for people.
Creating new usable follicles could eventually address a different problem from transplanting an existing donor supply. Reliable human results, growth direction, long-term cycling, safety and scalable production would still need to be demonstrated. The paper does not establish unlimited donor hair or a commercialization date.
| Approach | Research goal | Evidence boundary |
|---|---|---|
| AI-designed anti-androgen drugs | Target signaling involved in follicle miniaturization | AH-001 has company-reported early human safety findings; regrowth benefit remains to be established. |
| Follicle reactivation | Restore activity in existing follicles | PP405 has early human data and a recruiting Phase 2/3 trial. The cited sources do not establish that it was AI-designed. |
| Follicle engineering / hair cloning | Generate additional functioning follicles | Primarily preclinical in the cited work; not an established replacement for transplantation. |
Read the source: Hair follicle organ regeneration with an accessory cell population · AnHorn: AH-001 Phase 1 completion announcement · ClinicalTrials.gov: PP405 AWAKEN, NCT07819435
Clascoterone: later-stage research to watch
Cosmo's July 23, 2026 update reports positive 12-month Phase 3 efficacy and safety data for clascoterone 5% topical solution in androgenetic alopecia. It targets a U.S. regulatory submission in the first quarter of 2027 and a European submission in the second quarter. Those are the developer's plans, not guaranteed filing, approval or availability dates.
This is a separate drug program from AH-001 and PP405. Neither a company's use of AI elsewhere nor a topical route establishes that this candidate was AI-designed, will have fewer side effects for an individual or will restore receded temples.
Read the source: Cosmo: Clascoterone Phase 3 and regulatory filing plans
The next 5–10 years: possibilities, not a timetable
Our editorial interpretation is that better treatment options are plausible as these programs mature. The cited evidence cannot assign a reliable probability, launch year or date for a permanent, medication-free cure. AI can help discover a candidate; clinical testing must still establish what it does for patients.
More targeted medicines, stronger reactivation of existing follicles and the creation of new follicles are distinct possibilities with different technical and clinical hurdles. A successful new medicine would not automatically deliver the same hairline changes as surgery, and an engineered follicle in a mouse does not establish an alternative available to patients.
Rather than treating 2027–2030 or 2029–2035 as established clinical timelines, watch for full controlled human results, adequate follow-up, regulatory decisions and actual access. Keep a diagnosis and an individualized discussion of current options separate from speculation about the pipeline.
Read the source: bioRxiv: AI-enabled discovery for hair follicle rejuvenation · Hair follicle organ regeneration with an accessory cell population · Cosmo: Clascoterone Phase 3 and regulatory filing plans
Questions to take to a clinician
Research progress is a reason to stay informed, not to assume a cure is imminent or that surgery is automatically the right next step. Use official trial records for study contacts and eligibility; we do not sell experimental products or arrange access to them.
Hairline Desk can organize clinic information, itemized costs, date inquiries and the practical details of comparing options. Diagnosis, prescriptions, candidacy and treatment decisions stay with qualified clinicians. Our concierge fee does not include medical treatment or guarantee a clinical result.
- What is causing my hair loss, and is it still progressing?
- Which areas have miniaturized hair, and what can reasonably improve?
- What are the benefits, risks, alternatives and follow-up for each option?
- Would treatment or monitoring change a transplant's timing, design or donor requirements?
- If I am interested in a trial, what are the official eligibility criteria, uncertainties and participant protections?
- What evidence would justify changing the plan, rather than waiting indefinitely for a possible future treatment?
Read the source: AAD: Hair loss diagnosis and treatment · ClinicalTrials.gov: PP405 AWAKEN, NCT07819435
Sources & scope
Published by Hairline Desk, a service of Inova Platforms, Inc. This is editorial education and planning information, not a clinician-reviewed treatment recommendation. Your clinical team determines suitability, treatment and individual recovery instructions. Sources checked November 2, 2026.
- Pelage: PP405 Phase 2a results announcement
Manufacturer-reported exploratory regrowth subgroup; not a head-to-head comparison with established treatments.
- ClinicalTrials.gov: PP405 Phase 2a, NCT06393452
Completed 78-participant study. Posted results cover safety, tolerability and pharmacokinetics; distinguish these from the sponsor's regrowth announcement.
- ClinicalTrials.gov: PP405 AWAKEN, NCT07819435
Phase 2/3 trial record, updated October 28, 2026: recruiting, estimated enrollment 600, actual study start September 21, 2026. Status and estimates can change.
- Pelage: AWAKEN first-patient dosing announcement
October 14, 2026 manufacturer announcement. Its publication date is different from the registry's study-start date.
- Aging Cell: TPP1 and hair follicle stem cells
Published August 28, 2026. TELODIN findings are experimental mouse research, not a treatment trial in people with male-pattern hair loss.
- GHK-Cu: small randomized split-eyebrow study
May 2026 proceedings report: 18 adults, 12 weeks, eyebrow hypotrichosis. These results do not establish scalp hairline restoration.
- MLPH: IGF-1 signaling and human hair shaft elongation
Online February 12, 2026, in the March journal issue. Isolated human follicles and mouse experiments, not a human scalp-treatment trial.
- BMC Biotechnology: DualPep-ALO preclinical study
Published April 13, 2026. Cell and human scalp-tissue models; laboratory comparisons do not establish clinical equivalence to minoxidil.
- JDD: Peptides for Hair Growth and Treatment of Hair Loss and Alopecia
Systematic review published online October 30, 2026. Publisher abstract: November 3, 2025 search, 981 records identified, 14 human studies included. Recommendation grades are not regulatory approval.
- AAD: Hair loss diagnosis and treatment
Diagnosis, established treatment options, limits and the need for an individual discussion of benefits and adverse effects.
- AAD: Hair transplantation and continued hair loss
Transplant assessment, donor hair, results and the possibility of continued thinning after surgery.
- DailyMed: Propecia prescribing information
Label limits for bitemporal recession and adverse-effect information. A label is not an individual prescribing recommendation.
- FDA: Compounding substances with potential safety risks
The injectable GHK-Cu entry describes potential immunogenicity and limited human safety data. It does not equate topical cosmetics with injectable products.
- bioRxiv: AI-enabled discovery for hair follicle rejuvenation
Preprint posted June 12, 2026; not peer reviewed. Four compounds were evaluated in cells and follicle organoid models, not a patient-treatment trial. Authors disclose commercial interests.
- XtalPi: Hair-loss program enters IND-enabling studies
October 2, 2026 company announcement. Preclinical pharmacology, safety and manufacturing work supports a possible future trial application; it is not human efficacy evidence.
- AnHorn: AH-001 Phase 1 completion announcement
October 30, 2025 company report of early human safety and tolerability for an AI-designed topical androgen-receptor degrader. It does not establish durable hair-regrowth efficacy.
- Hair follicle organ regeneration with an accessory cell population
RIKEN/OrganTech-associated study, online February 20, 2026. Cultured cells, engineered skin and mouse experiments; not an established human hair-cloning service.
- Cosmo: Clascoterone Phase 3 and regulatory filing plans
July 23, 2026 company update reports positive 12-month Phase 3 data and targets U.S. filing in Q1 2027 and Europe in Q2 2027. These are sponsor plans, not approval or launch dates.
Our checklists and comparisons are our own planning approach. How we source and publish · Report an error or ask a question.